EcoDrugPlus

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSHBUG00000021744
Gene Symbol: LOC102306161
3 Cross references
198 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSHBUG00000005834
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSHBUG00000020611
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSHBUG00000019071
Gene Symbol: EGLN2
3 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSHBUG00000015449
Gene Symbol: EGLN3
3 Cross references
197 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSHBUG00000022820
Gene Symbol: EPAS1
3 Cross references
210 Possible Orthologues:

Endothelin B Receptor-Like

Ensembl ID : ENSHBUG00000007051
Gene Symbol: LOC102303139
3 Cross references
197 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSHBUG00000013032
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSHBUG00000008640
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSHBUG00000022366
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSHBUG00000004423
Gene Symbol: EDNRB
3 Cross references
195 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSHBUG00000000570
Gene Symbol: EZH2
3 Cross references
228 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).